Oculis Holding Ag · NASDAQ:OCS
Oculis — FY2023 Earnings Presentation
11 slides from Oculis's earnings presentation, Mar 19, 2024
Slide 1: Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
Exhibit 99.1 Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress • A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND trial for Diabetic Macular Edema (DME), and Phase 3 OPTIMIZE-1 trial for i
Slide 2: Recent Highlights and Upcoming Clinical Milestones
• Achieved a record completion of patient enrolment for the Phase 2b RELIEF trial of OCS-02 (Licaminlimab), a specifically designed ophthalmic formulation of a TNFα inhibitor, eye drop formulation specifically designed with a proprietary antibody fragment technology to treat ocular inflammation. The
Slide 3: Q4 and Full Year 2023 Financial Results and Non-IFRS Information
• General and administrative expenses were CHF 4.3 million or $4.9 million for the three-months ended December 31, 2023. G&A expenses remained in-line with the same period in 2022, which was CHF 4.4 million or $4.6 million. • Q4 Net loss was CHF 12.5 million or $14.1 million for the fourth quarter e
Slide 4: Consolidated Statements of Financial Position
(Unaudited)” table below for a reconciliation of these non-IFRS measures to the most directly comparable IFRS measures. Consolidated Statements of Financial Position
Slide 5: Consolidated Statements of Financial Position (CHF thousands)
(Amounis in CHF thousaneis) ASSETS ‘Non-current assets Property and equipment, net Intangible assets Right-of-use assets Other non-current assets Total non-current assets Current assets (Other current assets Accrued income Short-term financial assets ‘Cash and cash equivalents Total current assets T
Slide 6: Oculis
Ocullis
Slide 7: Consolidated Statements of Loss
Consolidated Statements of Loss
Slide 8: Reconciliation of Non-IFRS Measures (Unaudited)
Reconciliation of Non-IFRS Measures (Unaudited)
Slide 9: Reconciliation of Non-IFRS Measures (CHF thousands, except per share data)
(Amounts in CHF thousands, except per share data) For the years ended ended December 31, 2023 2022 2021 IFRS loss for the period (68,502) 5,098) (8582) Non-JFRS adjustments: ‘Merger and listing expense () 34863 7 zZ Merger Sub 2 reclassification from equity to foreign exchange oss 4978 2 : ‘Non-IFRS
Slide 10: About Oculis
About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macula
Slide 11: Forward-Looking Statements
inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee,